An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...

在当今社会，肥胖已成为影响人们健康的重要因素之一。你是否也曾为体重困扰而苦恼？最近，丹麦制药巨头诺和诺德（Novo Nordisk）开发的新型注射式肥胖症药物amycretin在临床试验中展现出惊人的减重效果，给这场与礼来（Eli Lilly）的竞争带来了新的希望。

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...

Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...